Allogenes lead compound is in a registrational trial, which significantly impacts both clinical and commercial risk. Genocury has revolutionized CAR T treatment, as lymphodepletion contributed to 5 patients dying during P1 Azer-cel trials. The FDA released a statement last year concerning the safety of CAR T.
Basically, Azer-cel won't be first to market and allogeneic CAR T is going to be replaced by in vivo CAR T as the latest revolutionary technology. These points dramatically impact perceived and actual pipeline value.
IMU Price at posting:
2.4¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)